MGI Tech Unveils New European Headquarters in Berlin, Germany

Expanding Partnerships

MGI's expansion follows a stellar start to the year, marked by groundbreaking partnerships across Europe. In February, MGI collaborated with MetaGenoPolis in France, providing the DNBSEQ-T7 ultra-high throughput sequencer for the "Le French Gut" project and other research under the Million Microbiomes from Humans Project (MMHP).

In March, MGI partnered with Eurofins Genomics Europe Genotyping A/S, securing the first corporate order of the revolutionary DNBSEQ-T20×2 ultra-high throughput sequencer in Europe. This milestone paves the way for significant advancements in precision health initiatives across the continent.

Recently, MGI showcased its extensive lab automation and sequencing products at ECCMID 2024 and announced a technical assessment of the ABL DeepChek® assays by ABL Diagnostics on its DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of the DeepChek® assays will be conducted on the newly launched DNBSEQ-E25.

Future Prospects

“We have experienced positive growth and formed many valuable partnerships in the region in recent years. Establishing our new European headquarters will enable us to sustain this momentum to empower more users,” said Duncan Yu, President at MGI. “We look forward to witnessing further advancements by providing an optimal customer experience and facilitating collaboration for greater omics access and capabilities in Europe and globally.”

For more information about the G400 Developer Program, please visit here.